# A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

> **NCT06970665** · PHASE4 · RECRUITING · sponsor: **Astellas Pharma Inc** · enrollment: 20 (estimated)

## Conditions studied

- Geographic Atrophy
- Age-Related Macular Degeneration

## Interventions

- **DRUG:** avacincaptad pegol

## Key facts

- **NCT ID:** NCT06970665
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-08
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06970665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06970665, "A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06970665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*